Effects of rivastigmine on the appetite of patients with Alzheimer's disease (Relationship of BuChE activity and ghrelin level in blood)
- Conditions
- Alzheimer's disease
- Registration Number
- JPRN-UMIN000015596
- Lead Sponsor
- Ichihino Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
Patients who fall into one of the following criteria will be excluded from this study: 1) Patients with neurodegenerative disease, schizophrenia, bipolar disorder, or other disease classified in DSM-IV Axis I 2) Patients with DLB, or other systemic disease or neurological disorder (dysthyroidism, vitamin B12 or folic acid deficiency, after head injury, Huntington disease, Parkinson's disease, intradural hematoma, normal pressure hydrocephalus, brain tumor, syphilis, etc.) 3) Patients diagnosed as having VD, or possible VD based on NINDS-AIREN diagnostic criteria 4) Patients with severe cardiovascular disorder 5) Patients with bradycardia (< 50bpm), sick sinus syndrome, or conduction disturbance 6) Patients with acute, severe, or unstable symptoms of asthma 7) Patients showing hypersensitiveness to components of rivastigmine or to carbamate derivative 8) Patients after operation of gastrectomy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method * Amount of change of blood active and inactive ghrelin * Change of BuChE activity
- Secondary Outcome Measures
Name Time Method * Mean amount of weekly food intake * Amount of change of body weight * Psychological attitude including appetite * Cognitive ability assessed by HDS-R * Adverse event